Health Condition 1: J399- Disease of upper respiratory tract, unspecified
Conditions
Interventions
Intervention1: Zedocef CV: Cefpodoxime Proxetil 200mg + Clavulanic acid 125 mg Tab_Twice daily after meal (Approx 12 hr apart) Orally for 10 days
Control Intervention1: Tab Clavam: Amoxicillin 500 Plu
Sponsors
Dr Rajendra Bohra
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male or female patients aged between 18 to 65 years of age (both ages inclusive) 2. Diagnosed with URTIs with presence of at least four of the following signs and symptoms: -Sneezing -Runny nose -Nasal congestion -Cough -Fever -Headache -Malaise -Chilliness -Scratchy throat -Sore throat -Hoarseness -Myalgias -Post nasal drip -Purulent rhinorrhea -Difficulty in swallowing 3. Women of childbearing potential must be willing to consistently use an appropriate method of contraception 4. Willingness to give their written informed consent to participate in the study 5. Willingness to comply with all aspects of the protocol
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity to active or inactive ingredients of the IP or other β-lactams (e.g., penicillins and cephalosporins) except study treatment. 2.Patients with known history of clostridium difficile-associated diarrhea 3. History of renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, serum sickness-like reaction, hemorrhage, agranulocytosis, and pancytopenia 4. History of patients with mononucleosis 5. Present chronic inflammatory ENT and respiratory tract disease 6. Obstructive anatomic lesions in the nasopharynx 7. Patients with severe or complicated course of the URTIs 8. Patients with signs of acute lower respiratory tract disease 9. Current symptoms mainly induced by other acute Ear-Nose-Throat (ENT) disease 10. Female patient with vaginal fungal infections or vulvovaginal infection 11. Current indication for administration of or treatment with antiviral drugs. 12. Treatment with glucocorticosteroids, immunomodulators, or antihistamines during the past 4 weeks prior to or at enrolment as well as current indication requiring these drugs during the trial. 13. Patients requiring hospitalization or parenteral antibiotic treatment. 14. Patients who have received any antibiotic treatment within 2-3 days prior to enrollment in the study. 15. Heavy smoking, alcohol abuse or known or suspected drug addiction. 16. Female patients who are pregnant or lactating or planning to become pregnant. 17. Evidence or history of clinically significant medical or surgical abnormality including clinically significant laboratory parameters that, in the opinion of the investigator, would put the patient at risk through study period, or would affect the study analyses if the disease exacerbates during the study. 18. Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of Cefpodoxime Clavulanic acid versus Amoxicillin Clavulanic acid in the clinical signs and symptoms of URTI on Day 11Timepoint: Day 11 | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the improvement in the clinical signs and symptoms of URTI on Day 5 and Day 11 in both treatment groups To determine the worsening in the clinical signs and symptoms of URTI on Day 5 and Day 11 in both treatment groups Global assessment of treatment improvement in the clinical signs and symptoms of URTI on Day 11 in both treatment groups To estimate the CRP level on Day 11 in both treatment groups Timepoint: Day 5 and Day 11 | — |
Countries
India
Contacts
Public ContactDr Rajendra Bohra
Mahatma Gandhi Mission Medical College And Hospital
Outcome results
None listed